Caplyta phase 3 data show rapid, significant mania symptom relief in bipolar I by day 3, sustained to week 3, with tolerable adverse effects.
|Podcasts|September 27, 2019
How to Talk to Patients About Bipolar Disorder
Author(s)Chris Aiken, MD
The bipolar word can be frightening or confusing to patients, but there are ways to talk about it that engage them in recovery. More in this podcast.
Advertisement
How to talk about bipolar disorder, with Chris Aiken, MD
The bipolar word can be frightening or confusing to patients, but there are ways to talk about it that engage them in recovery. More in this podcast.
Advertisement
Related to this article
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
Advertisement
Advertisement